Food-based supplement for adults with fatty liver disease linked to metabolic problems
Tests a supplement made from nopal, cacao and cricket in adults with MASLD.
Plain-language title generated from the registry record
Registry title: Effect of Ancestry Supplementation in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Key facts
- Where
- Guadalajara, MexicoSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07592013, who can take part
Where in Mexico
- Institute of Molecular Biology in Medicine and Gene TherapyGuadalajara, MexicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Guadalajara
- Trial code
- NCT07592013
- Record updated
- 5 November 2026
- Original description
The goal of this clinical trial is to evaluate the effect of Ancestry, a supplement made from Mexican-origin foods (nopal, cacao, and cricket) in adults with Metabolic dysfunction-associated steatotic liver disease (MASLD). The main questions it aims to answer are:Read full original descriptionShow less
Effect of Ancestry Supplementation on the Abundance of Beneficial Bacterial Genera in the Gut Microbiota in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to evaluate the effect of Ancestry, a supplement made from Mexican-origin foods (nopal, cacao, and cricket) in adults with Metabolic dysfunction-associated steatotic liver disease (MASLD). The main questions it aims to answer are:
* Does the supplementation with Ancestry improve the hepatic steatosis grade in participants with MASLD? * Does the supplementation improve biochemical and anthropometric parameters in participants with MASLD? * Does the supplementation enrich the abundance of beneficial bacteria in the gut microbiota of participants?
Researchers will compare the supplement group to a placebo group to see if the supplement is effective.
Participants will:
* Take the supplement or a placebo every day for 3 months. * Receive nutritional guidance from a trained dietitian to control dietary intake. * Attend follow-up clinic visits every month for monitoring and checkups.
Inclusion: Mexican mestizo adults of both sexes between 18 to 60 years old; Diagnosis of MASLD according to the criteria established by the American Association for the Study of Liver Diseases; Controlled Attenuation Parameter (CAP) score >248 dB/m, liver stiffness <14 kPa according to FibroScan Expert 630 (Echosens, Paris, France); Obesity diagnosed by body fat percentage; Bristol stool scale type 3-4; Physical inactivity according to the International Physical Activity Questionnaire (IPAQ); Alcohol consumption <20 grams/day for women and <30 grams/day for men; Signed informed consent.
Exclusion: Current or prior 6 weeks consumption of probiotic formulations; Current or prior 2 months consumption of antibiotics or antiparasitic drugs before the start of the study; Frequent consumption (greater than or equal to twice a week) of anti-inflammatory drugs, analgesics, or medications that alter normal intestinal function (e.g., laxatives, enemas, antidiarrheal agents, etc.); Previous malabsorptive bariatric surgery (gastric bypass, sleeve gastrectomy), restrictive bariatric surgery (adjustable gastric band), or cosmetic surgical procedures (liposuction, lipo-sculpture, abdominoplasty, etc.) in the last 2 years; Severe gastrointestinal diseases (e.g., chronic constipation, Crohn's disease, celiac disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, etc.), autoimmune diseases, and malignant neoplasms; Allergy or intolerance to cacao, nopal, or crickets; Current consumption of dietary supplements (omega-3 fatty acids, thermogenics, protein, teas, etc.); Pregnant women, women planning pregnancy, or breastfeeding women; Weight loss greater than three kilograms in the last month; Tobacco consumption.